1443240-06-9

Upstream product

• 1019024-79-3 6-fluoro-[1,2,4] triazolo[4,3-a]pyridine 
• 1443242-57-6 2,2,2-trifluoro-N-[(S)‐4‐carbonyl-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide 
• 23357-52-0 (S)-1,2,3,4-tetrahydronapht-1-yl-amine 
• 1351997-20-0 (1R,4S)-aminoN-(S)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-ol 
• 1443242-59-8 2,2,2-trifluoro-N-((1S,4R)-4-hydroxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-acetamide 
• 1443243-60-4 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((R)-3-triisopropylsilanyloxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea 
• 1443243-59-1 (1S,4R)-4-[3-((R)-3-triisopropylsilanyloxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine 
• 1443243-58-0 6-fluoro-3-((R)-3-triisopropylsilanyloxy-pyrrolidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridine 
• 1443243-57-9 (R)-1-(6-fluoro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-pyrrolidin-3-ol 
• 1020036-49-0 3-chloro-6-fluoro-[1,2,4]triazolo[4,3-a]pyridine 

Relevant academic research and scientific papers

KINASE INHIBITORS

Compounds of formula (I) or a pharmaceutically acceptable salt thereof: formula (I) wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

KINASE INHIBITORS

Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.